Navigation Links
Vaccine shows promise in preventing mono
Date:12/10/2007

A new study suggests that a vaccine targeting Epstein-Barr virus (EBV) may prevent infectious mononucleosis, commonly known as mono or glandular fever. The study is published in the December 15 issue of The Journal of Infectious Diseases, now available online.

EBV is a member of the herpes virus family and one of the most common viruses in humans, with nearly all adults in developed countries such as the United States having been infected. EBV is often asymptomatic but commonly causes infectious mononucleosis, with 30 to 40 percent of adolescents who contract the virus developing the disease. EBV is also associated with a number of other diseases, some of the most serious being lymphomas and other lymphoproliferative diseases in people with compromised immune systems, such as transplant patients. Despite the frequency of EBV infections and infectious mononucleosis, the new study is the first to suggest the efficacy of a vaccine in preventing infectious mononucleosis.

The study was conducted by Etienne M. Sokal, MD, PhD, and colleagues at several Belgian institutions and pharmaceutical companies. The vaccine targets glycoprotein 350, a protein that facilitates the entry of EBV into immune system cells. In this preliminary, Phase II clinical trial, 181 young adults who had not previously been infected by EBV received three doses of either a placebo or the vaccine.

During the 18-month observation period, the proportion of symptomatic EBV infections was reduced from 10 percent (nine out of 91) in the control group to 2 percent (two out of 90) in the vaccinated group, indicating that those who did not receive the vaccine were almost 5 times more likely to develop infectious mononucleosis.

With these promising results in a small group of subjects, Dr. Sokal suggested the next step should be large-scale studies on the benefit in healthy subjects and ability to prevent acute EBV infection and post-transplant lymphoproliferative diseases in transplant patients. He added, There is currently no possibility to prevent or to treat acute mononucleosis, which has remained so far an unmet medical problem. This vaccine may decrease the socio-economic impact of acute mononucleosis.

Development of an EBV vaccine has had a slow and problematic history. These results suggest that the prevention of infectious mononucleosis is possible, and provide a framework for future trials looking to prevent more serious consequences of EBV infection.

In an accompanying editorial, Henry H. Balfour, Jr., MD, of the University of Minnesota Medical School, noted the importance of such studies on EBV vaccines, especially because the worldwide disease burden due to EBV is enormous. Balfour agreed that these findings should stimulate future research and larger clinical trials on the prevention and treatment of diseases associated with EBV.


'/>"/>

Contact: Steve Baragona
sbaragona@idsociety.org
703-299-0412
Infectious Diseases Society of America
Source:Eurekalert

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... , ... “Letters From Home”: a moving compilation of letters that remind ... “Letters From Home” is the creation of published author, John Allred, a passionate leader ... Savelle Ministries International, who has traveled and ministered on four continents. , “It is ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... other tick-borne diseases through research, education and awareness, today announced the appointment of ... immunologist and microbiologist, Dr. Sellati has more than 20 years of research experience ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability Indices ... – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality in ... afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves staring at ...
(Date:9/21/2017)... Church, VA (PRWEB) , ... September 21, 2017 ... ... Policy , **An FDAnews Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the competitive ... edge they can get while staying in compliance with FDA rules. , The ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... Bill Howe ... to its customers, and give back to the community. For over 37 years, they ... most successful companies serving plumbing in San Diego. They were chosen as ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)... OrthoAtlanta has been named the official orthopedic and sports ... the 2018 College Football Playoff (CFP) National Championship to be ... Atlanta, Georgia . OrthoAtlanta is proud to ... in many activities leading up to, and including the national ... OrthoAtlanta ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/9/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... lasmiditan, an investigational, oral, first-in-class molecule for the acute ... to placebo in the Phase 3 SPARTAN study. Detailed ... of the International Headache Society (IHC) in ... demonstrate lasmiditan,s potential to reduce pain and provide freedom ...
Breaking Medicine Technology: